Abstract:Background: In the past two decades, a large-scale survey of hemoglobinopathies and thalassemia was carried out in mainland China, involving nearly one million people in 28 provinces. The incidences of hemoglobin (Hb) variants, α-thalassemia and β-thalassemia were 0.33%, 2.64% and 0.66%, respectively. The chemical structural analysis identified 67 Hb variants. Among them, 20 are new variants. The analysis of the α-globin gene organization in 111 HbH patients showed 76 cases (68.5%) were of the deletion type, 8 had Hb Constant Spring and the other cases were of non-deletion type. The results of the molecular characterization of more than 200 β-thalassemia alleles showed that the most common types of β-thalassemia mutations in China are CD 41/42 (−4 bp), IVS-II-nt.654 C→T, CD 17 A→T, CD 71/72 (+A) and −28 A→G. Methods: To explore the simple method for molecular diagnosis of β-thalassemia, multiplex allele-specific amplification (MAS-PCR) was used that could simultaneously detect the above five common types of β-thalassemia mutations. Results: Based on the molecular analysis of β-thalassemia intermedia, β-thalassemia homozygotes or compound heterozygotes combined with α-thalassemia, as well as the conjunctive abnormalities of β-thalassemia heterozygote with triplicated haplotype of α-globin genes, were the most common cause of thalassemia intermedia in China. We also used the RT-PCR quantitation method to show that the most common β-thalassemia allele, IVS-II-nt.654 C→T, still produced a small amount (about 15%) of normally spliced β-globin mRNA, therefore, causing β+-thalassemia. In clinical trials of hydroxyurea (HU) treatment for β-thalassemia patients, we found that HU may enhance the expression of the β-globin gene in some patients, leading to an alleviation of clinical symptoms. In the studies of the reversal of aberrant splicing of IVS-II-nt.654 C→T allele by the antisense approach, we constructed a mammalian expression vector that can produce an antisense RNA targeting against the aberrant splice sites of IVS-II-nt.654 C→T pre-mRNA. Conclusions: The results indicated that the antisense RNA produced from the vector could efficiently suppress the aberrant splicing pattern and restore the correct splicing pathway in vitro and in vivo, leading to the improvement of globin chain biosynthesis in thalassemia cells.

Cloning of Human Thalassemic Mutation Β41/42 and Establishment of Its Mammalian Expression System

Cloning of human thalassemic mutation β~(41/42) and establishment of its mammalian expression system

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

Study on the Cloning and Expression of Human Fibrinogen α ,β, γ Gene

Study on the Cloning and Expression of Human Fibrinogen Α,β,γ Gene

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

Therapeutic Effects of Induced Pluripotent Stem Cells in Chimeric Mice with Β-Thalassemia.

Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

Transcriptome Analyses of β-Thalassemia −28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs)

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of β-thalassemia mutant by base editor in human embryos

[Cloning of Human Beta2-Microglobulin Gene and Efficient Expression in Escherichia Coli].